

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. **3**)

INHIBIKASE THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, \$0.001 par value

(Title of Class of Securities)

45719W205

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP 45719W205
Number(s):

1	Names of Reporting Persons Perceptive Advisors LLC
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☒ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 10,320,875.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 10,320,875.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 10,320,875.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 6.9 %	
12	Type of Reporting Person (See Instructions) IA	

SCHEDULE 13G

CUSIP Number(s):	45719W205
------------------	-----------

1	Names of Reporting Persons Joseph Edelman	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☒ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 10,320,875.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 10,320,875.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 10,320,875.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	

11	Percent of class represented by amount in row (9) 6.9 %
12	Type of Reporting Person (See Instructions) IN

SCHEDULE 13G

CUSIP 45719W205
Number(s):

1	Names of Reporting Persons Perceptive Life Sciences Master Fund, Ltd.	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☒ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization CAYMAN ISLANDS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 10,320,875.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 10,320,875.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 10,320,875.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 6.9 %	
12	Type of Reporting Person (See Instructions) CO	

SCHEDULE 13G

Item 1.

- (a) Name of issuer:
INHIBIKASE THERAPEUTICS, INC.
- (b) Address of issuer's principal executive offices:
1000 N. West Street, Suite 1200, Wilmington, DE, 19801

Item 2.**(a) Name of person filing:**

The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value \$0.001 per share (the "Common Stock") of INHIBIKASE THERAPEUTICS, INC. (the "Issuer") are:

- (i) Perceptive Advisors LLC ("Perceptive Advisors")
- (ii) Joseph Edelman ("Mr. Edelman")
- (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")

(b) Address or principal business office or, if none, residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor, New York, NY 10003

(c) Citizenship:

Perceptive Advisors is a Delaware limited liability company.
Mr. Edelman is a United States citizen.
The Master Fund is a Cayman Islands corporation.

(d) Title of class of securities:

Common Stock, \$0.001 par value

(e) CUSIP No.:

45719W205

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership**(a) Amount beneficially owned:**

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 139,535,900 shares of Common Stock outstanding as of August 4, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2026, and assume the exercise of Warrants (as defined below) held by the Reporting Persons for 10,320,875 shares of Common Stock.

Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock or Warrants. The Master Fund directly holds (i) pre-funded warrants (the "Pre-Funded Warrants") to purchase 790,000 shares of Common Stock at an exercise price of \$0.001 per share, (ii) common warrants to purchase 3,357,211 shares of Common Stock at an exercise price of \$1.37 per share, and (iii) common warrants to purchase 6,173,664 shares of Common Stock at an exercise price of \$1.49 per share (together with the Pre-Funded Warrants, the "Warrants"). The terms of the Warrants provide that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding. As of the date hereof, this limitation permits the Reporting Persons to exercise Warrants for up to 10,320,875 shares of Common Stock. Perceptive Advisors serves as the investment manager of the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.

(b) Percent of class:

Perceptive Advisors: 6.9%
Mr. Edelman: 6.9%
Master Fund: 6.9%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Perceptive Advisors: 0
Mr. Edelman: 0
Master Fund: 0

(ii) Shared power to vote or to direct the vote:

Perceptive Advisors: 10,320,875
Mr. Edelman: 10,320,875
Master Fund: 10,320,875

(iii) Sole power to dispose or to direct the disposition of:

Perceptive Advisors: 0
Mr. Edelman: 0
Master Fund: 0

(iv) Shared power to dispose or to direct the disposition of:

Perceptive Advisors: 10,320,875
Mr. Edelman: 10,320,875
Master Fund: 10,320,875

Item 5. Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Perceptive Advisors LLC

Signature: /s/ Joseph Edelman

Name/Title: Joseph Edelman, Managing Member

Date: 08/14/2026

Joseph Edelman

Signature: /s/ Joseph Edelman

Name/Title: Joseph Edelman

Date: 08/14/2026

Perceptive Life Sciences Master Fund, Ltd.

Signature: /s/ Joseph Edelman

Name/Title: Joseph Edelman, Managing Member

Date: 08/14/2026